Rhizoma Dioscoreae Nipponicae attenuates airway remodeling and angiogenesis-related changes in asthma with altered mTOR/4EBP1/HIF-1α/VEGF pathway markers☆ Authors: Xiaoqing Zhou, Zhen Wang, Suqun Zheng Published: 2026 ABSTRACT BackgroundAsthma is a chronic inflammatory airway disease characterized by airway remodeling and hyperresponsiveness. Angiogenesis is a key contributor to airway remodeling and disease progression. Rhizoma Dioscoreae Nipponicae (RDN), a traditional Chinese medicine, has shown anti-inflammatory and anti-angiogenic potential, but its effects on asthma-associated airway remodeling remain unclear.MethodsThe chemical profile of the RDN extract was characterized using UHPLC-Q Exactive Orbitrap MS/MS. An ovalbumen-induced mouse model of asthma and C166 mouse endothelial cells were used to examine the effects of RDN treatment. Histopathological changes were assessed using H&E and Masson's trichrome staining. mRNA and protein expression levels of key components in the mTOR/4EBP1/HIF-1α/VEGF signaling pathway were analyzed by qPCR and Western blot.ResultsUHPLC-Q Exactive Orbitrap MS/MS analysis tentatively annotated 2509 constituents and demonstrated good batch-to-batch chemical consistency of the RDN extract. Compared with the model group, RDN treatment significantly reduced the airway inflammation score by approximately 39.5% (P < 0.01), an effect comparable to that of prednisone. It also decreased the collagen area ratio by approximately 62.7% (P < 0.05). RDN also significantly decreased the protein levels of mTOR, 4EBP1, HIF-1α, and VEGF in both lung tissue and C166 cells (P < 0.05).ConclusionRDN alleviated airway inflammation and remodeling at the histopathological level, and these effects were associated with downregulation of markers within the mTOR/4EBP1/HIF-1α/VEGF pathway. These findings suggest that RDN may be a promising therapeutic agent for ameliorating airway remodeling in asthma. Future studies incorporating analyses of phosphorylation states are warranted to further clarify the underlying mechanisms. Introduction Asthma is a heterogeneous respiratory disease characterized by chronic airway inflammation, airway hyperresponsiveness, and episodic but reversible airflow obstruction,1 and it typically presents with recurrent wheezing and dyspnoea.2 The rising global incidence of asthma underscores its substantial public health burden.3 Airway hyperresponsiveness, chronic inflammation, and airway remodeling are the 3 major pathological hallmarks of asthma, among which airway remodeling is a key driver of long-term disease progression.4 Airway remodeling involves structural alterations such as airway smooth muscle hypertrophy, basement membrane thickening, collagen deposition, and neovascularization,5 which ultimately lead to irreversible airway narrowing.6 Angiogenesis further accelerates airway remodeling by increasing airway vascularity and facilitating inflammatory cell infiltration.7 Although inhaled corticosteroids in combination with long-acting β2-adrenergic receptor agonists are effective in controlling inflammation and alleviating symptoms, their ability to reverse established airway remodeling remains limited.8 Emerging biologics targeting type 2 inflammation have also shown potential to attenuate airway remodeling in severe asthma, as evidenced by improvements in airway wall thickness and mucus plugging.9,10 Therefore, therapeutic strategies targeting angiogenesis may be of considerable clinical value. Recent pharmacological studies suggest that traditional Chinese medicine (TCM) may represent a promising therapeutic approach for asthma, particularly by modulating inflammatory responses and inhibiting pathological angiogenesis.11 Rhizoma Dioscoreae Nipponicae (RDN) is a traditional anti-inflammatory herbal medicine12 and contains bioactive constituents, including dioscin and polysaccharides, with antioxidant and immunomodulatory activities.13 Studies have shown that dioscin and its major metabolite, diosgenin, which share steroid-like structures, can ameliorate airway remodeling in vitro and in animal models of asthma.14, 15, 16 Furthermore, these compounds have been reported to inhibit angiogenesis under certain pathological conditions.17,18 However, the mechanisms by which RDN regulates airway angiogenesis in asthma remain unclear. Vascular endothelial growth factor (VEGF), a key mediator of angiogenesis, is markedly upregulated in asthma and correlates with airway remodeling. VEGF expression is regulated by hypoxia-inducible factor-1α (HIF-1α),19 which is activated under hypoxic conditions to promote VEGF expression.20 Recent evidence indicates that the mechanistic target of rapamycin (mTOR) pathway regulates HIF-1α translation through its downstream effector, eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1).21 Specifically, activated mTOR phosphorylates 4EBP1, causing it to dissociate from eukaryotic translation initiation factor 4E (eIF4E), thereby enhancing HIF-1α translation, upregulating VEGF expression, and promoting angiogenesis. The mTOR/4EBP1/HIF-1α/VEGF signaling axis has been implicated in cancer and diabetic retinopathy,22 but its role in asthmatic airway remodeling remains unclear. Here, we systematically investigated the effects of RDN on airway angiogenesis and remodeling in asthma using an ovalbumin-induced murine model and the mouse endothelial cell line C166. We further examined whether RDN treatment was associated with alterations in the mTOR/4EBP1/HIF-1α/VEGF signaling axis during airway remodeling. Together, these experiments were designed to provide preliminary histological and molecular evidence for the effects of RDN on airway remodeling in asthma. Methods Animals, preparation of the RDN extract, and UHPLC-Q Exactive Orbitrap MS/MS analysis Animals A total of 24 female BALB/c mice (6–8 weeks old, 18 ± 2 g) were purchased from HFK Bioscience (Beijing, China). The mice were housed in a pathogen-free facility at the Zhonghong Boyuan Animal Experiment Center. The temperature was maintained at 24 ± 2 °C under a 12-h light/dark cycle. Mice had free access to standard chow and water. All procedures were approved by the Animal Care and Use Committee (approval no. LL-202312130005) and were performed in accordance with relevant institutional guidelines. Preparation of the RDN extract The identity of RDN (Chinese name: Chuanshanlong) was verified using the Medicinal Plant Names Services database (http://mpns.kew.org). The dried rhizome used to prepare the RDN extract was obtained from the Pharmacy of Zhejiang Chinese Medical University and authenticated by Prof. Shui Li Zhang (Department of Resource Identification, School of Pharmacy, Zhejiang Chinese Medical University). A standard decoction procedure was used: the herb was extracted twice with distilled water, first at a ratio of 1:10 (w/v) and then at 1:8 (w/v), with each extraction lasting 1 h. The combined extracts were filtered through gauze and concentrated under reduced pressure to yield a final suspension equivalent to 1 g/mL crude herb. The extract was aliquoted into sterile 100-mL bottles and steam-sterilized at 100–105 °C for 30 min. The final preparation was stored at −20 °C until use. Phytochemical profiling and batch consistency evaluation of the RDN extract by UHPLC-Q Exactive Orbitrap MS/MS To assess batch-to-batch consistency, 3 independently prepared batches of the RDN extract were analyzed under identical conditions. Samples were analyzed using a Thermo UltiMate 3000 ultra-high-performance liquid chromatography system coupled to a Q Exactive mass spectrometer (Thermo Fisher Scientific, USA). Chromatographic separation was performed on an ACQUITY UPLC HSS T3 column (2.1 × 100 mm, 1.8 μm). Mass spectrometric data were acquired using an electrospray ionization (ESI) source in both positive and negative ion modes. Full-scan MS data were collected at a resolution of 70,000 over an m/z range of 81–1000, followed by HCD-MS/MS analysis at a collision energy of 30 eV and an MS/MS resolution of 17,500. Total ion chromatograms (TICs) and base peak chromatograms (BPCs) were acquired to generate chemical fingerprints of the samples. Representative constituents were tentatively identified based on retention times, precursor-ion m/z values, and MS/MS fragmentation patterns. In addition, selected constituents were subjected to semiquantitative analysis based on relative peak areas, and the corresponding relative standard deviation (RSD) values were calculated to evaluate batch-to-batch consistency. Establishment of the mouse model and treatments After 7 days of acclimatization, the 24 mice were randomly assigned to 4 groups: a control group, a model group, a model + RDN group, and a model + prednisone group. An asthma model was established by ovalbumen (OVA) sensitization.23 On days 1 and 7, mice received intraperitoneal injections of 200 μL OVA sensitization solution containing 50 μg OVA and aluminum hydroxide. Beginning on day 15, mice were challenged once daily for 14 consecutive days with nebulized 5 mg/mL OVA in saline for 30 min. Treatments were administered by gavage starting on day 15, once daily for 14 days. The model + RDN group received RDN extract (10 g/kg//d),24 and the model + prednisone group received prednisone (5 mg/kg/d).25 Equal volumes of saline were administered to the control and model groups. Twenty-four hours after the final challenge, all animals were euthanized by cervical dislocation for subsequent analyses. Haematoxylin and eosin (H&E) staining After bronchoalveolar lavage, lung tissue designated for histological analysis was fixed in 4% formaldehyde. Following fixation, samples were dehydrated through a graded ethanol series, embedded in paraffin, and sectioned at 4–5 μm. The sections were deparaffinized and rehydrated sequentially in xylene, 100% ethanol, and 75% ethanol. The sections were then stained with haematoxylin solution (ZLI-9610, Zhongshan Jinqiao) for 5 min and rinsed with running water for approximately 1 min to remove excess stain. The sections were subsequently counterstained with eosin solution (G1100, Solarbio) for 2 min. After staining, the sections were dehydrated, cleared, and mounted. Histological changes were observed under a light microscope at 200 × and 400 × magnification. Inflammatory cell infiltration in H&E-stained lung sections was evaluated in a blinded manner using a semiquantitative five-point grading scale, as described previously.26 Briefly, peribronchial and perivascular inflammation was scored as follows: 0, normal; 1, a few inflammatory cells; 2, a ring of inflammatory cells 1 cell layer deep; 3, a ring of inflammatory cells 2 to 4 cell layers deep; and 4, a ring of inflammatory cells more than 4 cell layers deep. Five randomly selected, non-overlapping fields from each lung section were assessed, and the average score was calculated as the inflammation score for each animal. Masson's trichrome staining A Masson's trichrome staining kit (G1006, Servicebio) was used to stain fixed lung tissue sections. Sections were immersed in Masson's A solution and incubated for approximately 15 h at room temperature (about 25°C). The sections were then rinsed with running water for about 30 s until the yellow color disappeared, followed by incubation in Masson A solution again for 30 min at 65°C according to the established protocol. Masson D and F solutions were preheated in an oven at 65°C. The sections were stained for 1 min in a mixture of equal volumes of Masson B and C solutions and then rinsed under running water. The sections were differentiated in 1% hydrochloric acid alcohol for approximately 1 min until the nuclei appeared gray-black against an almost colorless or light gray background, and were then rinsed under running water. Excess water was gently removed, and the sections were stained with Masson's D solution for 10 min. The sections were briefly drained, immersed in Masson E solution for about 2 min, and then incubated in Masson F solution for 25 s. Finally, the sections were dehydrated through a graded ethanol series, cleared, and mounted. Sections were examined under a light microscope at 200 × and 400 × magnification for airway remodeling and collagen deposition. The collagen area ratio was quantified using ImageJ software (NIH, Bethesda, MD, USA). For each Masson-stained section, 5 randomly selected, non-overlapping peribronchial fields were analyzed at 200 × magnification. The blue-stained collagen fiber area and the total tissue area in each field were measured, and the collagen area ratio (%) was calculated as follows: Collagenarearatio(%)=CollagenfibreareaTotaltissuearea×100%. The mean value of all fields from each section was used for statistical analysis. Real-time quantitative PCR(RT-qPCR) analysis of signaling pathway components in lung tissue Frozen lung tissue designated for molecular analysis was ground into a fine powder in liquid nitrogen. Total RNA was extracted from an appropriate amount of powdered tissue using an Ultra-Pure Total RNA Extraction Kit (5003050, Xinjing Biotech) according to the manufacturer's instructions. RNA concentration and purity were measured using a NanoDrop microvolume spectrophotometer (Thermo Fisher Scientific). Then, 1 μg of total RNA was reverse-transcribed into cDNA using an All-in-One First-Strand cDNA Synthesis Kit (7316050, Xinjing Biotech) according to the manufacturer's instructions. qPCR reaction mixtures were prepared by combining 1 μL cDNA from each sample with QuantFast SYBR Green qPCR SuperMix (M221, Maibo Biotech). qPCR was performed on a CFX96 real-time PCR detection system. β-Actin served as the reference gene. Western blot analysis of signaling pathway proteins in lung tissue Total protein was extracted from frozen lung tissue designated for protein analysis using T-PER Tissue Protein Extraction Reagent (78510, Thermo Fisher Scientific). Protein concentrations were determined using a BCA Protein Assay Kit (P0010, Beyotime). Extracted proteins were separated by SDS-PAGE and transferred onto PVDF membranes (IPVH00010, Millipore). After blocking with 5% nonfat milk in TBST, the membranes were incubated overnight at 4 °C with the following primary antibodies: Raptor (2280), mTOR (2983), 4EBP1 (9644), and eIF4E (2067) from Cell Signaling Technology; and β-actin (ab8226), VEGFA (ab214424), and HIF-1α (14179) from Abcam. The membranes were then incubated for 1 h at room temperature with goat anti-mouse IgG (31160, Thermo Fisher Scientific) or goat anti-rabbit IgG (31210, Thermo Fisher Scientific) secondary antibodies. Protein bands were visualized using ECL chemiluminescent reagent (Thermo Fisher Scientific), and band intensities were quantified using ImageJ software (NIH). β-Actin was used as the loading reference for normalisation. Preliminary optimization of C166 cell treatment conditions The mouse endothelial cell line C166 (Cell Bank of the Chinese Academy of Sciences) was cultured in high-glucose DMEM supplemented with 10% fetal bovine serum (FBS) and penicillin–streptomycin. Cells were dissociated with 0.25% trypsin and passaged. After passaging, cells were treated with various concentrations of MHY1485 (an mTOR activator; SML0810, Selleck), rapamycin (an mTOR inhibitor; S1039, Selleck), and RDN-containing serum for 48 h. Cell viability was assessed using a CCK-8 assay to determine the optimal treatment concentrations. Based on the preliminary results, C166 cells were treated with 2 μM MHY1485, 5% RDN-containing serum, and 20 μM rapamycin for 0, 24, 48, and 72 h to determine the optimal treatment duration. Experimental grouping and treatment of C166 cells The mouse endothelial cell line C166 (Cell Bank of the Chinese Academy of Sciences) was cultured in high-glucose DMEM supplemented with 10% FBS and penicillin–streptomycin at 37 °C in 5% CO2 until cells reached approximately 90% confluence. Cells were dissociated with 0.25% trypsin and passaged. After passaging, cells were assigned to 5 groups: (1) control group, cultured under normal conditions without drug treatment; (2) model group, treated with 2 μM MHY1485 (SML0810, Selleck) for 48 h; (3) treatment group, treated with 2 μM MHY1485 plus 5% RDN-containing serum for 48 h; (4) rapamycin group, treated with 20 nM rapamycin (S1039, Selleck) for 48 h; and (5) RDN serum group, treated with 5% RDN-containing serum for 48 h. After treatment, cells were harvested for subsequent RT-qPCR and Western blot. RT-qPCR analysis of C166 cells C166 cells were cultured and treated as described in Section 2.8. Total RNA was extracted as described in Section 2.5, and RNA concentration was measured by spectrophotometry. Reverse transcription and real-time PCR were performed to assess the mRNA expression levels of mTOR pathway components. Each sample was analyzed in triplicate. Western blot analysis of C166 cells C166 cells were cultured and treated as described in Section 2.8. Protein was extracted using RIPA buffer containing protease inhibitors, as described in Section 2.6. Protein quantification, electrophoresis, membrane transfer, and antibody incubation were performed using the same protocol as that used for lung tissue samples. Immunoreactive bands were visualized and quantified by densitometric analysis. Statistical analysis C166 cells were cultured and treated as described in Section 2.8. Protein was extracted using RIPA buffer containing protease inhibitors, as described in Section 2.6. Protein quantification, electrophoresis, membrane transfer, and antibody incubation were performed using the same protocol as that used for lung tissue samples. Immunoreactive bands were visualized and quantified by densitometric analysis. Results UHPLC-Q Exactive Orbitrap MS/MS characterization of the RDN extract LC-MS profiles and tentative annotation of constituents in the RDN extract The 3 independently prepared batches of the RDN extract exhibited highly similar TIC and BPC profiles in both positive- and negative-ion modes. The major peaks showed comparable retention times and distribution patterns (Fig. 1), and no obvious batch-specific peaks or missing major peaks were observed, indicating that the overall chemical composition of the RDN extract was stable across batches. A total of 2509 constituents were tentatively annotated in the RDN extract (Appendix 1), including 1555 and 954 constituents detected in the positive- and negative-ion modes, respectively. Based on annotation confidence levels, 396, 1,687, and 426 constituents were assigned to levels 1, 2, and 3, respectively. Chemical classification indicated that the annotated constituents were mainly distributed among the superclasses of lipids and lipid-like molecules, organic acids and derivatives, organic heterocyclic compounds, benzenoids, organooxygen compounds, and phenylpropanoids and polyketides. Representative annotated constituents included diosgenin and diosmetin. Together, these data provide a preliminary characterization of the chemical profile and major constituent classes of the RDN extract.Fig. 1UHPLC-Q Exactive Orbitrap MS/MS TIC (A) and BPC (B) profiles of 3 independently prepared batches of the RDN extract in positive- and negative-ion modes. UHPLC-Q Exactive Orbitrap MS/MS TIC (A) and BPC (B) profiles of 3 independently prepared batches of the RDN extract in positive- and negative-ion modes. Semiquantitative comparison of representative constituents across batches of the RDN extract Semiquantitative analysis of 5 representative constituents based on relative peak areas showed generally comparable values across the 3 batches of the RDN extract, with only minor inter-batch variation (Appendix 2). The RSDs ranged from 2.052% to 7.370%, all below 10%, indicating good batch-to-batch consistency at the level of representative constituents. Although slight fluctuations were observed for several constituents, the overall variation was limited and did not affect the assessment of batch-to-batch consistency. RDN improves airway histopathology in asthmatic mice H&E staining results As shown in Fig. 2, the lung architecture of the control group was intact, with a continuous and orderly bronchial epithelium, no evident peribronchial inflammatory cell infiltration, and normal airway wall thickness. By contrast, the model group displayed marked thickening of the bronchial walls, narrowed airway lumens, disrupted and partially detached epithelium, and many infiltrating inflammatory cells, predominantly surrounding the bronchi and blood vessels, indicating that the asthma model had been successfully established. Compared with the model group, pathological airway damage in the prednisone-treated group was notably alleviated, with significantly reduced airway wall thickness, diminished inflammatory infiltration, and overall preserved airway structure. Similarly, the RDN-treated group showed considerable pathological improvement compared with the model group, including reduced airway wall thickness, decreased inflammatory cell infiltration, and a more orderly epithelial arrangement. Although the degree of improvement was slightly less pronounced than that observed in the prednisone group, the results suggested that RDN exerted anti-inflammatory effects nearly comparable to those of prednisone.Fig. 2HE staining and semi-quantitative inflammation scoring of lung tissue in each group. (A) Representative HE-stained lung sections showing pathological changes (magnification:×200 and × 400). (B) Semi-quantitative inflammation scores based on HE-stained sections. Data are expressed as mean ± SD (n = 6). ∗P < 0.05 vs. model group. HE, haematoxylin and eosin; RDN, Rhizoma Dioscoreae Nipponicae. HE staining and semi-quantitative inflammation scoring of lung tissue in each group. (A) Representative HE-stained lung sections showing pathological changes (magnification:×200 and × 400). (B) Semi-quantitative inflammation scores based on HE-stained sections. Data are expressed as mean ± SD (n = 6). ∗P < 0.05 vs. model group. HE, haematoxylin and eosin; RDN, Rhizoma Dioscoreae Nipponicae. Masson staining results Masson's trichrome staining was used to assess collagen fiber deposition in lung tissue. As shown in Fig. 3, minimal collagen staining was observed around the bronchi in the control group, with thin bronchial walls and no evidence of airway remodeling. By contrast, the model group exhibited significantly thickened bronchial walls and extensive collagen deposition (blue staining), indicating pronounced airway remodeling and fibrosis. These pathological changes further supported the successful establishment of the asthma model. Compared with the model group, the prednisone-treated group had markedly reduced collagen deposition, as evidenced by the decreased area of blue staining, and the bronchial structure appeared nearly restored to normal. The RDN-treated group also showed reduced collagen accumulation and improved bronchial morphology compared with the model group. Although the extent of collagen reduction was slightly less than that in the prednisone group, it was significantly improved compared with the model group, indicating that, like prednisone, RDN also attenuated airway remodeling and collagen fiber deposition.Fig. 3Masson's trichrome staining and quantitative analysis of collagen deposition in lung tissue in each group. (A) Representative Masson's trichrome-stained lung sections showing collagen deposition and airway remodeling (magnification:×200 and × 400). (B) Quantitative analysis of collagen area ratio. Data are expressed as mean ± SD (n = 6). ∗P < 0.05 vs. model group. RDN, Rhizoma Dioscoreae Nipponicae. Masson's trichrome staining and quantitative analysis of collagen deposition in lung tissue in each group. (A) Representative Masson's trichrome-stained lung sections showing collagen deposition and airway remodeling (magnification:×200 and × 400). (B) Quantitative analysis of collagen area ratio. Data are expressed as mean ± SD (n = 6). ∗P < 0.05 vs. model group. RDN, Rhizoma Dioscoreae Nipponicae. RDN downregulates mRNA expression of mTOR/4EBP1/HIF-1α/VEGF signaling pathway components in lung tissue RT-qPCR was used to measure the mRNA expression levels of 6 key genes, namely, Raptor, mTOR, 4EBP1, EIF4E, HIF-1α, and VEGF, as shown in Fig. 4A–F. Raptor and mTOR are central components of the mTORC1 complex; 4EBP1 and eIF4E regulate cap-dependent translation downstream of mTOR; HIF-1α and VEGF mediate hypoxia-driven angiogenesis as distal effectors.Fig. 4mRNA expression levels of mTOR pathway components in asthmatic lung tissue measured by RT-qPCR: A, Raptor; B, mTOR; C, 4EBP1; D, EIF4E; E, HIF; and F, VEGF. ∗P < 0.05 vs. control group, #P < 0.05 vs. model group. RDN, Rhizoma Dioscoreae Nipponicae. mRNA expression levels of mTOR pathway components in asthmatic lung tissue measured by RT-qPCR: A, Raptor; B, mTOR; C, 4EBP1; D, EIF4E; E, HIF; and F, VEGF. ∗P < 0.05 vs. control group, #P < 0.05 vs. model group. RDN, Rhizoma Dioscoreae Nipponicae. All 6 genes were substantially more highly expressed in the model group than in the control group (P < 0.05 vs. control group), indicating marked activation of the mTOR/4EBP1/HIF-1α/VEGF signaling pathway under pathological conditions. The groups receiving RDN or prednisone intervention had significantly reduced expression levels of these genes (P < 0.05 vs. model group), suggesting that both treatments were associated with reduced expression of pathway-related genes to a certain extent. Prednisone exerted more potent inhibitory effects than RDN on Raptor, mTOR, and 4EBP1. For Raptor, the mean reductions produced by prednisone and RDN were 103.97 (95% CI: 73.86 to 134.08) and 52.84 (95% CI: 20.62 to 85.07), respectively (Fig. 4A). For mTOR, the corresponding reductions were 79.79 (95% CI: 27.37 to 132.22) and 73.62 (95% CI: 22.26 to 124.97), respectively (Fig. 4B). For 4EBP1, the reductions were 1145.04 (95% CI: 474.13 to 1815.95) and 1128.36 (95% CI: 457.32 to 1799.41), respectively (Fig. 4C). The 2 treatments produced comparable reductions in EIF4E, with mean reductions of 39.50 (95% CI: 7.93 to 71.07) and 39.93 (95% CI: 12.20 to 67.66), respectively (Fig. 4D), and in HIF-1α, with reductions of 3491.27 (95% CI: 474.70 to 6507.84) and 3481.87 (95% CI: 465.20 to 6498.54), respectively (Fig. 4E). By contrast, RDN demonstrated a more pronounced downregulation of VEGF, with a mean reduction of 253.63 (95% CI: 121.78 to 385.47) compared with 244.68 (95% CI: 110.14 to 379.21) for prednisone (Fig. 4F). Although both interventions effectively attenuated the activity of this signaling cascade, the expression levels of all genes remained elevated relative to the control group, indicating that both treatments exerted only partial inhibitory effects on this pathway. RDN suppresses protein levels of mTOR/4EBP1/HIF-1α/VEGF signaling pathway components in lung tissue To validate the transcriptional changes observed by RT-qPCR at the protein level, we next examined the mTOR/4EBP1/HIF-1α/VEGF signaling pathway by Western blot analysis, using β-actin as an internal loading control. As shown in Fig. 5A, in contrast to the control group, the model group showed noticeably higher levels of Raptor (Fig. 5B), mTOR (Fig. 5C), 4EBP1 (Fig. 5D), eIF4E (Fig. 5E), HIF-1α (Fig. 5F), and VEGF (Fig. 5G), indicating substantial activation of this signaling axis under pathological conditions (P < 0.05 vs. control group).Fig. 5Western blot measurements of protein levels of mTOR pathway components in asthmatic lung tissue. Representative Western blots of Raptor, mTOR, 4EBP1, eIF4E, HIF-1α, VEGF, and β-actin. B–G, qPCR levels: B, Raptor; C, mTOR; D, 4EBP1; E, EIF4E; F, HIF; and G, VEGF. ∗P < 0.05 vs. control group, #P < 0.05 vs. model group. RDN, Rhizoma Dioscoreae Nipponicae. Western blot measurements of protein levels of mTOR pathway components in asthmatic lung tissue. Representative Western blots of Raptor, mTOR, 4EBP1, eIF4E, HIF-1α, VEGF, and β-actin. B–G, qPCR levels: B, Raptor; C, mTOR; D, 4EBP1; E, EIF4E; F, HIF; and G, VEGF. ∗P < 0.05 vs. control group, #P < 0.05 vs. model group. RDN, Rhizoma Dioscoreae Nipponicae. Treatment with RDN significantly reduced the protein levels of Raptor, mTOR, HIF-1α, and VEGF expression (P < 0.05 vs. model group), whereas its downregulation of 4EBP1 and EIF4E did not reach statistical significance. By contrast, prednisone administration suppressed all 6 proteins (P < 0.05 vs. model group). These findings indicated that RDN was associated with partial downregulation of several proteins related to the mTOR/4EBP1/HIF-1α/VEGF pathway, although to a lesser extent than prednisone. RDN downregulates mRNA expression of mTOR/4EBP1/HIF-1α/VEGF signaling pathway components in C166 mouse endothelial cells MHY1485 treatment significantly increased the mRNA expression of Raptor, mTOR, 4EBP1, eIF4E, HIF-1α, and VEGF in C166 cells compared with the control group (P < 0.05 vs. control group), as shown in Fig. 6A–F, consistent with mTOR signaling pathway activation. Co-treatment with RDN markedly suppressed MHY1485-induced upregulation, as evidenced by significant reductions in the transcript levels of all 6 genes compared with the MHY1485 group (P < 0.05 vs. MHY1485 group). These findings suggest that RDN was associated with attenuation of MHY1485-induced upregulation of pathway-related gene expression under stimulated conditions.Fig. 6mRNA expression levels of mTOR pathway components in C166 cells measured by RT-qPCR. (A–F), MHY1485-stimulated model: A, Raptor; B, mTOR; C, 4EBP1; D, EIF4E; E, HIF-1α; and F, VEGF. (G–L), rapamycin-stimulated model: G, Raptor; H, mTOR; I, 4EBP1; J, EIF4E; K, HIF-1α; and L, VEGF (rapamycin and RDN intervention). ∗P < 0.05 vs. control group, #P < 0.05 vs. MHY1485 group. RDN, Rhizoma Dioscoreae Nipponicae. mRNA expression levels of mTOR pathway components in C166 cells measured by RT-qPCR. (A–F), MHY1485-stimulated model: A, Raptor; B, mTOR; C, 4EBP1; D, EIF4E; E, HIF-1α; and F, VEGF. (G–L), rapamycin-stimulated model: G, Raptor; H, mTOR; I, 4EBP1; J, EIF4E; K, HIF-1α; and L, VEGF (rapamycin and RDN intervention). ∗P < 0.05 vs. control group, #P < 0.05 vs. MHY1485 group. RDN, Rhizoma Dioscoreae Nipponicae. Rapamycin, a well-established mTOR inhibitor, significantly downregulated the mRNA expression of Raptor, mTOR, 4EBP1, EIF4E, HIF-1α, and VEGF compared with the control group (P < 0.05 vs. control group), as shown in Fig. 6G–L, confirming the pathway's sensitivity to pharmacological suppression. RDN treatment also reduced the expression of these signaling components, although the differences did not reach statistical significance. This observation suggests that RDN exerted a modulatory effect on the basal activity of the mTOR/4EBP1/HIF-1α/VEGF pathway without strongly altering pathway component expression levels under non-stimulated conditions. RDN suppresses protein levels of mTOR/4EBP1/HIF-1α/VEGF signaling pathway components in C166 mouse endothelial cells Fig. 7A presents representative Western blot images illustrating Raptor, mTOR, 4EBP1, eIF4E, HIF-1α, and VEGF protein levels under various treatment conditions. In a quantitative analysis of the protein levels (Fig. 7B–G), MHY1485 markedly enhanced the protein levels of all 6 components (P < 0.05 vs. the control group), confirming activation of the mTOR signaling pathway at the protein level. RDN co-administration significantly attenuated this upregulation, reducing levels of each protein (P < 0.05 vs. MHY1485 group). The changes in protein levels are consistent with the mRNA expression findings shown in Fig. 6, further supporting an association between RDN treatment and reduced expression of pathway-related proteins under MHY1485 stimulation. Further comparisons (Fig. 7H–M) revealed that rapamycin, a classical mTOR inhibitor, significantly suppressed Raptor, mTOR, 4EBP1, eIF4E, HIF-1α, and VEGF protein levels (P < 0.05 vs. control group), reflecting its potent inhibitory effects. RDN treatment also significantly reduced these protein levels; however, the magnitude of inhibition was not as great as that observed with rapamycin.Fig. 7Protein levels of mTOR pathway components in C166 cells were measured by Western blot. (A), representative Western blots of Raptor, mTOR, 4EBP1, EIF4E, HIF-1α, VEGF, and β-actin. (B–G), MHY1485-stimulated model: B, Raptor; C, mTOR; D, 4EBP1; E, EIF4E; F, HIF-1α; and G, VEGF. (H–M), rapamycin-stimulated model: H, Raptor; I, mTOR; J, 4EBP1; K, EIF4E; L, HIF-1α; and M, VEGF. ∗P < 0.05 vs. control group, #P < 0.05 vs. MHY1485 group. RDN, Rhizoma Dioscoreae Nipponicae. Protein levels of mTOR pathway components in C166 cells were measured by Western blot. (A), representative Western blots of Raptor, mTOR, 4EBP1, EIF4E, HIF-1α, VEGF, and β-actin. (B–G), MHY1485-stimulated model: B, Raptor; C, mTOR; D, 4EBP1; E, EIF4E; F, HIF-1α; and G, VEGF. (H–M), rapamycin-stimulated model: H, Raptor; I, mTOR; J, 4EBP1; K, EIF4E; L, HIF-1α; and M, VEGF. ∗P < 0.05 vs. control group, #P < 0.05 vs. MHY1485 group. RDN, Rhizoma Dioscoreae Nipponicae. Discussion Chronic airway inflammation, pathological angiogenesis, and airway remodeling are recognized hallmarks of asthma.27,28 In this study, H&E and Masson's trichrome staining showed that RDN markedly reduced collagen deposition and airway inflammation in an OVA-induced mouse model of asthma, consistent with attenuation of airway remodeling. Although the therapeutic effect of RDN was slightly less pronounced than that of prednisone, the positive control, RDN significantly ameliorated key pathological features of asthma. Subsequent RT-qPCR and Western blot analyses further showed that RDN reduced the expression of several mTOR/4EBP1/HIF-1α/VEGF pathway-related markers in lung tissue and, under MHY1485-stimulated conditions, in C166 endothelial cells. Notably, RDN attenuated MHY1485-induced changes consistent with pathway activation, supporting its potential to modulate pathological signaling. Collectively, these findings suggest that RDN may alleviate airway inflammation and remodeling, accompanied by altered expression of mTOR/4EBP1/HIF-1α-VEGF pathway-related markers, thereby providing a theoretical basis for its potential use as a TCM in asthma therapy.29 mTOR primarily mediates intracellular signal transduction by assembling into 2 distinct complexes, mTORC1 and mTORC2.30 Once activated, mTOR phosphorylates downstream signaling molecules, such as 4EBP1 and p70S6K1, thereby regulating various physiological processes, including cell survival, metabolism, and cytoskeletal remodeling.31,32 Moreover, accumulating evidence indicates that mTOR is a crucial mediator of pathological airway remodeling in asthma.33 Specifically, Peng et al demonstrated that inhibiting the PI3K/Akt/mTOR signaling pathway downregulated the expression of multiple cytokines and inflammatory mediators implicated in asthma pathogenesis, thereby alleviating asthma symptoms.34 Further research demonstrated that the PI3K/Akt/mTOR pathway was activated in asthmatic mice and that targeted inhibition of this pathway reduced NF-κB activity, thereby attenuating airway remodeling.35 Consequently, it is regarded as a potential therapeutic target for asthma.36 Consistent with these findings, our results showed that mTOR expression was significantly upregulated in asthmatic mice and was markedly attenuated after prednisone or RDN treatment. Among the downstream effectors of mTOR, eukaryotic translation initiation factor 4EBP1 is a pivotal regulator of protein synthesis. Under unstimulated conditions, 4EBP1 binds to eIF4E, suppressing cap-dependent mRNA translation. Upon activation, mTORC1 phosphorylates 4EBP1, which leads to its dissociation from eIF4E and the subsequent initiation of protein translation.37 This process is critical in asthma, as it promotes the synthesis of pro-inflammatory cytokines and growth-related proteins that drive airway inflammation, airway smooth muscle hypertrophy, and remodeling.38 In asthmatic models, enhanced mTOR/4EBP1 signaling has been observed, which correlates with increased airway smooth muscle proliferation and mucus hypersecretion.39 Pharmacological inhibition of the PI3K/Akt/mTOR pathway has been shown to suppress 4EBP1 phosphorylation, reduce inflammatory cytokine production, and attenuate airway remodeling.34 In line with this mechanism, our study showed that RDN reduced mTOR and 4EBP1 mRNA expression, whereas the reduction in total 4EBP1 protein in lung tissue did not reach statistical significance. These findings suggest that the mTOR/4EBP1 branch may contribute to the effects of RDN on airway remodeling. Vascular remodeling, characterized by pathological angiogenesis and increased vascular permeability, is a key feature of chronic asthma.40 Central to this process is the HIF-1α/VEGF axis. HIF-1α, stabilized under hypoxic and inflammatory conditions, upregulates VEGF expression, a potent mediator of neovascularization and vascular leakage.41 HIF-1α and VEGF are upregulated in asthmatic airways, promoting endothelial cell proliferation, greater vascular permeability, and airway wall thickening.42 Notably, HIF-1α and VEGF translation is regulated by the mTOR/4EBP1 pathway and therefore mechanistically links metabolic signaling and hypoxia-driven vascular remodeling.43 Furthermore, studies have demonstrated that corticosteroids such as budesonide can block the HIF-1α/VEGF axis and suppress airway vascular remodeling.44 Consistent with these observations, our data showed that RDN treatment significantly decreased HIF-1α and VEGF mRNA and protein levels in lung tissue and endothelial cells and was accompanied by histologically confirmed reductions in collagen deposition and inflammatory infiltration. Together, these results suggest that RDN may ameliorate airway remodeling in asthma, at least in part, by altering the mTOR/4EBP1/HIF-1α/VEGF Pathway markers. Notably, this study assessed total protein levels of mTOR and 4EBP1 without quantifying their phosphorylated forms. As the functional output of the mTOR/4EBP1 axis is predominantly governed by phosphorylation-dependent activation rather than protein abundance alone, our findings should be interpreted as correlative evidence of pathway modulation rather than direct demonstration of pathway inhibition. AHR, a key functional hallmark of asthma, was not assessed in the present study. Therefore, the observed histological and molecular changes should not be interpreted as definitive evidence of improved functional airway responsiveness or overall asthma severity. In the present study, RDN at 10 g/kg, a dose determined in pilot dose-finding experiments, produced measurable therapeutic effects in the current model. However, because only a single relatively high dose was formally evaluated, the dose-response relationship, minimum effective dose, optimal therapeutic range, and potential dose dependency of RDN remain undefined, and caution is warranted when extrapolating the present findings to a clinical context. From a safety perspective, RDN was well tolerated over the 28-day treatment period, with no mortality, no overt behavioral signs of systemic toxicity, and body weight gain comparable to that of the model mice. These observations suggest the absence of obvious short-term intolerance under the present experimental conditions. Nevertheless, the current safety evaluation was limited to general observations, as serum biochemical indices, hematological parameters, and histopathological examination of major organs were not performed. Further studies incorporating dose-ranging designs together with systematic toxicological assessment will be necessary to better define both the therapeutic window and the safety profile of RDN. Several limitations of this study should be acknowledged. First, the OVA-induced asthma model, although well-established and widely used in experimental settings, employs an allergen that is not a major sensitizing agent in human asthma. Common environmental allergens responsible for allergic asthma in humans include house dust mite, fungi such as Alternaria, and cockroach-derived antigens. Whether RDN exerts similar protective effects in models induced by these clinically relevant allergens warrants further investigation. Second, this study exclusively employed young female BALB/c mice. Asthma exhibits well-documented sex- and age-related differences in prevalence, clinical phenotypes, and therapeutic responses. For instance, adult females demonstrate higher disease severity and altered drug responsiveness compared to males, while elderly patients often present with distinct inflammatory profiles and comorbidities. Whether the effects of RDN on angiogenesis-related pathways are consistent across different sexes and age groups remains to be determined. particularly in inflammatory and signaling readouts. Third, in the present study, 6 animals per group were included, which is comparable to sample sizes used in previous exploratory studies employing similar experimental settings. Although statistically significant differences were observed in the primary endpoints, the sample size was not prospectively determined by a formal power analysis specifically for the mechanistic endpoints investigated here. Given the inherent variability of the model and the multiple group comparisons performed, the study may have had limited power to detect small or moderate effects in some mechanistic readouts. Further studies with larger cohorts and prospective power analyses will be necessary to strengthen the mechanistic conclusions. Fourth, C166 murine endothelial cells, although widely used in endothelial research, are not specific to the pulmonary microvasculature. The present findings using C166 cells should therefore be considered proof-of-concept evidence. Future studies using primary pulmonary microvascular endothelial cells or lung-derived endothelial lines are needed to recapitulate these results in a model more representative of the pulmonary vascular environment. Finally, given the often poor translation between preclinical findings in mice and clinical outcomes in humans, further validation in human studies will be necessary to confirm the therapeutic relevance of these findings in asthma patients. Conclusion In conclusion, our study showed that RDN attenuated airway inflammation and remodeling and was accompanied by altered mTOR/4EBP1/HIF-1α/VEGF pathway-related markers in vivo and in vitro. RDN also improved pathological features in the present models, including collagen deposition, inflammatory infiltration, and epithelial disruption. These findings support the potential of RDN as a candidate agent for alleviating airway remodeling and angiogenesis-related changes in asthma, although mechanistic confirmation and functional validation, including AHR assessment, are still needed. Abbreviations RDN, Rhizoma Dioscoreae Nipponicae; TCM, traditional Chinese medicine; VEGF, vascular endothelial growth factor; HIF-1α, hypoxia-inducible factor-1α; mTOR, mechanistic target of rapamycin; 4EBP1, 4E-binding protein 1; eIF4E, eukaryotic translation initiation factor 4E; ESI, electrospray ionization; TIC, Total ion chromatograms; BPC, base peak chromatograms; RSD, relative standard deviation; OVA, ovalbumin; RT-qPCR, Real-time quantitative; FBS, foetal bovine serum Authors’ consent for publication in WAO Journal All authors read and agree to publication in WAO Journal. Authors’ contributions XZ and SZ designed the study and analyzed and interpreted the data. XZ conducted pictures and tables. ZW reviewed and revised the article. All authors participated in the planning, implementation, and analysis. All authors read and agree to the published version of the manuscript. Ethics approval and consent to participate All animal procedures were approved by the Animal Ethics Committee of Zhonghong Boyuan (approval no. LL-202312130005) and conducted following NIH guidelines for laboratory animal care and use. Consent for publication All authors read and agree to the published version of the manuscript. Data availability statement The raw data supporting the conclusions of this article will be made available on request. Funding The work was supported by Zhejiang Provincial Traditional Chinese Medicine Science and Technology Program (No. 2023ZL039). Conflicts of interest The authors declare that there are no financial or commercial conflicts of interest.